NCT04460898View on ClinicalTrials.gov

RW Treatment Patterns and Outcomes in Postmenopausal HR+/HER2- mBC Patients Treated With Palbociclib Plus Letrozole as Initial Endocrine Therapy at Community Oncology Practices in the U.S.

CompletedOBSERVATIONAL
Enrollment

195

Participants

Timeline

Start Date

January 4, 2019

Primary Completion Date

June 24, 2019

Study Completion Date

June 24, 2019

Conditions
Breast Cancer
Trial Locations (1)

10017

Pfizer United States, New York

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT04460898 - RW Treatment Patterns and Outcomes in Postmenopausal HR+/HER2- mBC Patients Treated With Palbociclib Plus Letrozole as Initial Endocrine Therapy at Community Oncology Practices in the U.S. | Biotech Hunter | Biotech Hunter